Patents by Inventor Mohammed Sajad

Mohammed Sajad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190233441
    Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: April 2, 2019
    Publication date: August 1, 2019
    Applicant: Genentech, Inc.
    Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
  • TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180298033
    Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
  • Triazolopyridine compounds, compositions and methods of use thereof
    Patent number: 9873709
    Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
  • TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170226132
    Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 10, 2017
    Applicant: Genentech, Inc.
    Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
  • TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160185780
    Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: March 4, 2016
    Publication date: June 30, 2016
    Applicant: Genentech, Inc.
    Inventors: Nicholas C. RAY, Yun-Xing CHENG, Christine EDWARDS, Simon C. GOODACRE, Wei LI, Snahel PATEL, Matthew W. CARTWRIGHT, Mohammed SAJAD, Po-wai YUEN, Mark E. ZAK
  • Respiratory disease treatment
    Patent number: 9078885
    Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: July 14, 2015
    Assignee: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
  • Respiratory Disease Treatment
    Publication number: 20140248357
    Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.
    Type: Application
    Filed: April 7, 2014
    Publication date: September 4, 2014
    Applicant: PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
  • Respiratory disease treatment
    Patent number: 8815837
    Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: August 26, 2014
    Assignee: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
  • Respiratory Disease Treatment
    Publication number: 20120264787
    Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.
    Type: Application
    Filed: June 29, 2012
    Publication date: October 18, 2012
    Applicant: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Harry FINCH, Craig FOX, Mohammed SAJAD, Monique Bodil VAN NIEL, Andrew FORREST
  • Respiratory disease treatment
    Patent number: 8236786
    Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: August 7, 2012
    Assignee: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bodil Van Niel, Andrew Forrest
  • RESPIRATORY DISEASE TREATMENT
    Publication number: 20110053986
    Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.
    Type: Application
    Filed: August 4, 2010
    Publication date: March 3, 2011
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bodil Van Niel, Andrew Forrest